

BC Cancer Protocol Summary for Treatment of In-Transit Melanoma using Intralesional Aldesleukin (IL-2)

Protocol Code

SMILALD

Tumour Group

Skin and Melanoma

Contact Physician

Dr. Noelle Davis

ELIGIBILITY:

In-transit metastatic melanoma.

TESTS:

None

PREMEDICATIONS:

Acetaminophen 325 mg PO 30 to 60 minutes prior to treatment.

TREATMENT:

Supply:

Aldesleukin is supplied as vials containing 22 million units (MU).

Preparation and Dilution:

Aldesleukin 22 MU vial is reconstituted with 1.2 mL SWI using a chemo vent, directing diluent against side of vial. Swirl gently to mix. **DO NOT SHAKE.**

Vial contents are further diluted with 3.2 mL D5W to give 5 Million Units per mL.

A total volume of 4.4 mL is withdrawn into 8 x 0.55 mL syringes (using 1.0 mL luer-lock tip syringes).

Apply red syringe cap to each syringe

Store syringes refrigerated between 2 - 8 degrees Celsius for up to 48 hours. **DO NOT FREEZE.**

Administration (intralesional):

A 1/2 inch, 30-gauge needle is secured to each luer-lock tip syringe.

Each lesion is wiped with an alcohol swab prior to injection.

Approximately 0.1 mL is injected into each lesion.

Injections are repeated every 1 to 3 weeks for a total of 4 treatments per lesion.

DOSE MODIFICATIONS:

None

PRECAUTIONS:

1. **Pain and swelling** at the injection site(s) is to be expected. Usually mild and short-lived, this responds well to oral analgesics.
2. **Fever and flu-like symptoms** are common and be well managed with acetaminophen.

Call Dr. Noelle Davis or tumour group delegate at 604-875-5880 with any problems or questions regarding this treatment program.

REFERENCES:

1. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. *Cancer*. 2010 Sep 1;116(17):4139-46.
2. Temple-Oberle CF, Byers BA, Hurdle V, Fyfe A, McKinnon JG. Intralesional Interleukin-2 Therapy for In-Transit Melanoma. *J. Surg. Oncol*. 2014;109:327–331.
3. Boyd KU, Wehrli BM, Temple CLF. Intralesional interleukin-2 for the treatment of in-transit melanoma. *J Surg Oncol*. 2011 Dec;104(7):711-7.
4. pCODR Expert review committee final recommendation. Aldesleukin for in-transit melanoma. June 22, 2015.